%A CAO Min, WU Yun-Qiang, LU Ning, HUANG Jian-Guo %T The combination of trastuzumab and lapatinib added to neoadjuvant chemotherapy for breast cancer: a meta-analysis of randomized evidence %0 Journal Article %D 2015 %J Journal of International Oncology %R 10.3760/cma.j.issn.1673-422X.2015.04.008 %P 296-273 %V 42 %N 4 %U {https://gjzlx.sdfmu.edu.cn/CN/abstract/article_9642.shtml} %8 2015-04-08 %X ObjectiveTo compare the efficacy and safety of trastuzumab versus the combination of trastuzumab and lapatinib added to neoadjuvant chemotherapy in HER2positive breast cancer. MethodsWe searched PubMed, MEDLINE, The Cochrane Library, Web of Science, CNKI, Wanfang datebase and the abstracts of major international conferences in recent 5 years to identify randomized controlled trials which met the inclusion and exclusion criteria. Study selection and analyses were undertaken according to the Cochrane Handbook. Metaanalysis was performed using RevMan 5.0 software. ResultsFour trials were identified with 779 eligible patients. The results of metaanalyses showed that the rate of pathological complete response was significantly higher in the group receiving rastuzumab and tlapatinib than that in the group with trastuzumab alone (53.3%vs 38.8%，RR=1.39, 95 %CI： 1.201.63; P<0.001). No statistical differences were observed in regarding adverse events among patients receiving trastuzumab or the combination of trastuzumab and lapatinib, except the grade ⅢⅣ diarrhea (2.2%vs 25.6%，RR=11.54, 95%CI： 5.6923.41; P<0.001). ConclusionThe combination of trastuzumab and lapatinib added to neoadjuvant chemotherapy in HER2positive breast cancer is more effective, without more adverse reactions except diarrhea; it ia an effective and safe treatment.